CVS Stock Hits a 52-Week High — Is the Pharmacy Giant Finally Back?

Observing CVS Health regain investor favor is almost unexpected. This was the type of holding you didn’t boast about, and for a long time it was the stock that people discreetly avoided at dinner parties. Earnings calls were plagued by the Aetna acquisition. Retail store foot traffic appeared worn out. Benefit managers for pharmacies faced political criticism from all sides. The chart then abruptly began to bend in the opposite direction. With quarterly revenue that had finally surpassed $100 billion, CVS closed at $87.36 on May 7, 2026, just short of a new 52-week high.

The first quarter’s numbers were significantly better than most people had anticipated. Adjusted EPS was $2.57, which beat the Wall Street estimate of $2.18 by almost 18%. In the healthcare industry, this is the kind of number that gets analysts on the phone before lunch. Over $5 billion was surpassed in revenue. The full-year adjusted EPS guidance was increased by management to a midpoint of $7.40. Listening to the May 6 conference call gave me the impression that the company had changed in a way that the market hadn’t fully factored in.

In an interview with CNBC on the day of the report, CEO David Joyner bluntly stated that although the Aetna business “got off track,” five straight quarters of improvement have begun to mount. Executives typically don’t use language like that voluntarily. It indicates that the prior issue was genuine and that patience, not catchphrases, is being used to gauge the recovery. The cosmetics aisle, the photo counter that is hardly used anymore, and the pharmacy line that winds past the cold medicine are all still recognizable when you walk into a CVS today. However, behind the scenes, the integrated insurance-pharmacy-retail model is at last generating the kind of cash flow that detractors claimed it would never be able to.

A 33% return over the last year and about 42% over three years are expected for investors who persevered through the difficult period. These are not glamorous tech-stock figures, but they tell a more subdued and intriguing tale for a healthcare conglomerate that many had dismissed as bankrupt. It’s important to note that a person who purchased $1,000 worth of CVS five years ago would now own roughly $1,021. This indicates that the stock essentially moved sideways for five years prior to this most recent increase. It’s a recent recovery. Even more recent is the conviction that underlies it.

Wall Street has taken notice. The current lineup of analysts has 22 buy ratings compared to just 2 holds, which is uncommon for a stock this size and nearly unheard of for one with CVS’s kind of baggage. The price-to-earnings ratio of 62.80 makes conventional value investors wince, and technical indicators flash overbought—the RSI is above 70. One argument is that the rally has overreached itself. Another argument is that the market priced in the worst-case scenario for years and is only now beginning to recognize that the worst-case scenario might not have occurred.

As this develops, it’s difficult to ignore the larger trend in healthcare at the moment. The entire managed-care complex, including UnitedHealth, Elevance, and Cigna, has been faltering due to slower utilization trends, Medicare Advantage reimbursement disputes, and political pressure. Strangely, CVS is the one that is subtly outperforming. It’s really unclear if that will continue into the remainder of 2026. The company must contend with constant pressure on drug prices, the constant threat of new regulations, and the fact that retail pharmacy is a more difficult business than it once was. For the first time in a long time, however, CVS stock appears more like a business that just so happens to be doing the work than a turnaround project. Most people are unaware of how important that distinction is.